3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Breast Neoplasms
15
Triple Negative Breast Neoplasms
5
Ovarian Neoplasms
4
Prostatic Neoplasms
3
Melanoma
3
Lymphoma
3
Lung Neoplasms
3
Endometrial Neoplasms
3
Uterine Cervical Neoplasms
2
Multiple Myeloma
2
Locally Advanced (Inoperable) or Metastatic Breast Cancer
2
Leukemia
2
Hematologic Neoplasms
2
Healthy Participants
2
Disease Progression
2
Carcinoma, Non-Small-Cell Lung
2
Uterine Neoplasms
1
Urinary Bladder Neoplasms
1
Thyroid Neoplasms
1
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Recurrence
1
Rectal Neoplasms
1
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
1
Pancreatic Neoplasms
1
Neoplasms
1
Neoplasm Metastasis
1
Moderate Hepatic Impairment
1
Interventions
Rituximab
45
Cyclophosphamide
38
ibrutinib
22
fludarabine
22
acalabrutinib
21
venetoclax
20
zanubrutinib
17
Lenalidomide
17
Bendamustine Hydrochloride
17
obinutuzumab
16
fludarabine phosphate
14
Magnetic Resonance Spectroscopy
14
Cytarabine
14
Specimen Handling
13
CT-P10
13
pirtobrutinib
12
Biopsy
12
glofitamab
10
Etoposide
10
Whole-Body Irradiation
9
Vincristine
7
Peripheral Blood Stem Cell Transplantation
7
Mycophenolic Acid
7
Melphalan
7
Doxorubicin
7
brexucabtagene autoleucel
6
Cyclosporine
6
orelabrutinib
5
Methotrexate
5
Immunotherapy, Adoptive
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Lymphoma, Mantle-Cell
×
capivasertib
×
1 year
×
Clear all
No trials found.